Non-Small Cell Lung Cancer (NSCLC) - Current and Future Players

  • ID: 4032625
  • Report
  • 139 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Eli Lilly
  • Merck & Co.
  • Novartis
  • MORE
Non-Small Cell Lung Cancer (NSCLC) - Current and Future Players

Summary

The author has released their pharma report, “Non-Small Cell Lung Cancer (NSCLC) - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing NSCLC Market. The report identifies and analyses the key companies shaping and driving the global NSCLC market. The report provides insight into the competitive NSCLC landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by a team of industry experts.

Scope

- Investigation of current and future market competition for NSCLC
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of NSCLC sector through market impact analysis, future market scenario and company analysis

Reasons to buy

- Gain a high level view of the trends shaping and driving NSCLC market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- What’s the next big thing in the global NSCLC market landscape? Identify, understand and capitalize
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Eli Lilly
  • Merck & Co.
  • Novartis
  • MORE
1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Related Reports

3 Market Outlook

3.1 Global Markets

3.1.1 Forecast

3.1.2 Drivers and Barriers - Global Issues

4 Current and Future Players

4.1 Overview

4.2 Trends in Corporate Strategy

4.3 Company Profiles

4.3.1 Roche/Genentech

4.3.2 Eli Lilly

4.3.3 Pfizer

4.3.4 AstraZeneca

4.3.5 Bristol-Myers Squibb

4.3.6 Merck & Co.

4.3.7 Novartis

4.3.8 Boehringer Ingelheim

5 Appendix

5.1 Bibliography

5.2 Abbreviations

5.3 Methodology

5.4 Forecasting Methodology

5.4.1 Diagnosed NSCLC Patients

5.4.2 Percent Drug-Treated Patients

5.4.3 Drugs Included in Each Therapeutic Class

5.4.4 Launch and Patent Expiry Dates

5.4.5 General Pricing Assumptions

5.4.6 Individual Drug Assumptions

5.4.7 Generic Erosion

5.4.8 Pricing of Pipeline Agents

5.5 Primary Research - KOLs

5.5.1 KOLs

5.6 About the Authors

5.6.1 Analyst

5.6.2 Therapy Area Director

5.6.3 Epidemiologist

5.6.4 Global Head of Healthcare

5.7 About the Author

5.8 Disclaimer

1.1 List of Tables

Table 1: NSCLC - Global Drivers and Barriers, 2015?2025

Table 2: Key Companies in the NSCLC Market in the 8MM, 2015-2025

Table 3: Roche/Genentech’s NSCLC Portfolio Assessment, 2016

Table 4: Eli Lilly’s NSCLC Portfolio Assessment, 2016

Table 5: Pfizer’s NSCLC Portfolio Assessment, 2016

Table 6: AZ’s NSCLC Portfolio Assessment, 2016

Table 7: BMS’ NSCLC Portfolio Assessment, 2016

Table 8: Merck & Co.’s NSCLC Portfolio Assessment, 2016

Table 9: Novartis’ NSCLC Portfolio Assessment, 2016

Table 10: BI’s NSCLC Portfolio Assessment, 2016

Table 11: Key Launch Dates - Part I

Table 12: Key Launch Dates - Part II

Table 13: Key Patent Expiries

Table 14 Average Body Weight and Surface Area Across the 8MM

Table 15: Average Cost of Therapy of Alimta in the 8MM

Table 16: Average Cost of Therapy of Alecensa in the 8MM

Table 17: Average Cost of Therapy of Avastin

Table 18: Average Cost of Therapy of Cyramza

Table 19: Average Cost of Therapy of Gilotrif

Table 20: Average Cost of Therapy of Iressa

Table 21: Average Cost of Therapy of Portrazza

Table 22: Average Cost of Therapy of Tagrisso

Table 23: Average Cost of Therapy of Tarceva

Table 24: Average Cost of Therapy of Vargatef

Table 25: Average Cost of Therapy of Xalkori

Table 26: Average Cost of Therapy of Zykadia

Table 27: Average Cost of Therapy of Keytruda

Table 28: Average Cost of Therapy of Opdivo

Table 29: Average Cost of Therapy of Tecentriq

Table 30: Average Cost of Therapy of Conmana

Table 31: High-Prescribing Physicians Surveyed by Country

1.2 List of Figures

Figure 1: Global Sales for NSCLC (8MM), 2015-2025

Figure 2: Global Sales for NSCLC (8MM), 2015-2025

Figure 3: Global Sales for NSCLC (8MM), 2015-2025

Figure 4: Global Sales of Branded Products for NSCLC by Company, 2015-2025

Figure 5: Company Portfolio Gap Analysis in NSCLC, 2015-2025

Figure 6: Roche/Genentech SWOT Analysis in NSCLC, 2016

Figure 7: Eli Lilly SWOT Analysis in NSCLC, 2016

Figure 8: Pfizer SWOT Analysis in NSCLC, 2016

Figure 9: AZ SWOT Analysis in NSCLC, 2016

Figure 10: BMS SWOT Analysis in NSCLC, 2016

Figure 11: Merck & Co. SWOT Analysis in NSCLC, 2016

Figure 12: Novartis SWOT Analysis in NSCLC, 2016

Figure 13: BI SWOT Analysis in NSCLC, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Roche/Genentech
  • Eli Lilly
  • Pfizer
  • AstraZeneca
  • Bristol-Myers Squibb
  • Merck & Co.
  • Novartis
  • Boehringer Ingelheim
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll